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Alterations on mRNA processing are known to cause variable CF disease manifes-
tations which are difﬁcult to predict. Thus, characterization of the impact of these
CFTR mutations in native tissues becomes crucial for disease prognosis and choice
of adequate therapies.
Here, we aimed to characterize CFTR mutations affecting mRNA processing. CFTR
transcripts were analysed by semi-quantitative RT-PCR upon extraction from native
tissues of patients with F508del in one allele and one the following in the other:
711+1G>T, 1584+18672A>G, 1717−1G>A, 1812−1G>A, 3120+1G>A. Compari-
son of transcripts relative levels from both alleles (reference-F508del mRNA levels)
show that 1717−1G>A, 1812−1G>A, 3120+1G>A and 1716+18672A>G induce
transcripts degradation (63−80%). Notwithstanding, for 711+1G>T mutation no
decay of the transcripts was observed. Minigenes with IVS4art+IVS5 into full-
length CFTR cDNA were constructed to further characterize this abnormal mRNA
processing. HEK cell expressing the wt and 711+1G>T, 711+3A>G, 711+5G>A
mutant minigenes are analysed by RT-PCR and Western blot. Correct processing
of CFTR transcripts and protein was observed in the wt minigenes. In contrast, all
mutant minigenes originated alternative transcripts resulting in complete absence or
misprocessed protein. Compounds like Kinetin and EGCG shown to correct splicing
of transcripts from other genes are being tested in these CFTR minigenes. These
data may be of high relevance for CF personalized medicine for patients with these
splicing mutations.
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Objectives: In CF, genotype–phenotype correlations for the majority of CFTR
mutations are inhomogenous. Individual characterisation of CFTR function provides
a sensitive tool to describe the clinical relevance of CFTR variants with unknown
diagnostic consequence, and to directly quantify therapeutic effects of CFTR
modulating drugs. Aim of this study was to evaluate the organ-speciﬁc CFTR
dysfunction in sweat gland, respiratory and intestinal epithelium by comparison of
established CFTR biomarkers.
Methods: We included a total of 44 subjects (mean age 33 years, range 12−72):
PI-CF (n = 19), PS-CF (n = 11) and healthy controls (n = 14). Sweat test (L+R),
nasal potential difference (NPD) (L+R) and intestinal current measurement (ICM)
on rectal suction biopsies (n = 8/subject) were performed on the same day (ECFS
SOPs). Additionally, responsiveness to oral ivacaftor treatment was evaluated in 2
F508del/G551D patients by repetitive analysis of CFTR function.
Conclusion: Discriminative validity of ICM was excellent, providing the best diag-
nostic test to differentiate between PS-CF and non-CF, whereas CFTR dysfunction
followed a continuous gradient with borderline categories for sweat Cl− and NPD.
Ivacaftor increased mean CFTR function after 1 week to non-CF levels: Dsweat Cl−
−36.5mmol/l, D0Cl−/Iso −18.5mV (NPD), DForsk/IBMX +26.1mA/cm2 (ICM).
These organ-speciﬁc differences underline the relevance of functional CFTR anal-
ysis by a combination of CFTR biomarkers. Our data provide strong evidence that
ICM can be used for optimal translation of CFTR modulators from preclincial ex
vivo effect prediction to clinical in vivo conﬁrmation.
